Pemetrexed

Generic Name: Pemetrexed

Brand Names: Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁N_₅O_₆

CAS Number: 137281-23-3

Unique Ingredient Identifier: 04Q9AIZ7NO

Background: Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.

Indication: Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions: Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma

Associated Therapies: Monotherapy

Clinical Trials

SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer Metastatic

Interventions: Drug: AZD2014
Drug: Standard maintenance for squamous NSCLC
Drug: Durvalumab
Drug: AZD4547
Drug: Pemetrexed
Drug: AZD5363
Drug: AZD8931
Drug: Selumetinib
Drug: Vandetanib
Drug: savolitinib
Drug: Olaparib

First Posted Date: 2014-04-17

Last Posted Date: 2024-01-10

Lead Sponsor: UNICANCER

Target Recruit Count: 999

Registration Number: NCT02117167

Locations: 🇫🇷
Hôpital Avicenne, Bobigny, France
🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷
Institut Paoli Calmettes, Marseille, France

and more 34 locations

Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer

Phase 2

Terminated

Conditions: Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer

Interventions: Drug: AZD1775
Drug: AZD1775 Matching Placebo
Drug: pemetrexed
Drug: carboplatin

First Posted Date: 2014-03-14

Last Posted Date: 2017-03-29

Lead Sponsor: AstraZeneca

Target Recruit Count: 22

Registration Number: NCT02087241

Locations: 🇺🇸
Research Site, Nashville, Tennessee, United States

A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Carcinoma, Non-small Cell Lung

Interventions: Drug: Abemaciclib
Drug: LY3023414
Drug: Pemetrexed
Drug: Gemcitabine
Drug: Ramucirumab
Drug: Pembrolizumab

First Posted Date: 2014-03-06

Last Posted Date: 2020-09-11

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 142

Registration Number: NCT02079636

Locations: 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸
Indiana Cancer Pavilion, Indianapolis, Indiana, United States
🇺🇸
The West Clinic, Germantown, Tennessee, United States

and more 7 locations

The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer（NSCLC）

Phase 3

Conditions: Oligo-metastatic Stage IV Non-small Cell Lung Cancer

Interventions: Radiation: concurrent chemoradiotherapy
Drug: Docetaxel
Drug: pemetrexed
Drug: Cisplatin

First Posted Date: 2014-03-03

Last Posted Date: 2020-03-17

Lead Sponsor: Sichuan Cancer Hospital and Research Institute

Target Recruit Count: 420

Registration Number: NCT02076477

Locations: 🇨🇳
Sichuan Cancer Hospital & Institute, Chengdu, Sichuan, China

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

Phase 3

Completed

Conditions: Stage IV or Recurrent Non-Small Cell Lung Cancer

Interventions: Biological: Nivolumab
Drug: Gemcitabine
Drug: Cisplatin
Drug: Carboplatin
Drug: Paclitaxel
Drug: Pemetrexed

First Posted Date: 2014-01-22

Last Posted Date: 2023-03-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 541

Registration Number: NCT02041533

Locations: 🇯🇵
Local Institution - 0159, Akashi, Hyogo, Japan
🇺🇸
Southern Cancer Center, Inc., Mobile, Alabama, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

and more 138 locations